Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | VRK2 | Q86Y07 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23413882 | 0.87 | CA1 (0.43) | ALDH1A1HSD17B10CA1CA2CA9 | |
| SCHEMBL22466093 | 0.82 | ERN1 (0.56) | ERN1 | |
| SCHEMBL282282 | 0.80 | CA1 (0.41) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL5028742 | 0.80 | VCAM1 (0.38) | CA1CA2CA9ERN1VRK2 | |
| SCHEMBL1541882 | 0.76 | CA1 (0.41) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL806770 | 0.76 | ENPP2 (0.44) | — | |
| SCHEMBL29799726 | 0.76 | CA2 (0.42) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL13286805 | 0.74 | SERPINE1 (0.47) | TDP1CA1CA2MEP1B | |
| SCHEMBL20656519 | 0.74 | ALDH1A1 (0.37) | ALDH1A1HSD17B10TDP1CA1CA2 | |
| SCHEMBL1056064 | 0.73 | HSD17B10 (0.48) | ALDH1A1HSD17B10TDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200384134-A1 | IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20200384134-A1 | IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3321252-B1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | PUBLIC UNIV CORP YOKOHAMA CITY UNIV (JP) | 2020-10-21 | — | — | EP | disclosed |
| EP-3321252-B1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | PUBLIC UNIV CORP YOKOHAMA CITY UNIV (JP) | 2020-10-21 | — | — | EP | disclosed |
| CN-107922328-B | Novel compounds that specifically bind to AMPA receptors | 公立大学法人横滨市立大学 | 2020-05-19 | — | — | CN | disclosed |
| EP-3569229-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS | Public University Corporation Yokohama City University (JP) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569255-A1 | IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM | Public University Corporation Yokohama City University (JP) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569255-A1 | IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM | Public University Corporation Yokohama City University (JP) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569229-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH AMPA RECEPTORS | Public University Corporation Yokohama City University (JP) | 2019-11-20 | — | — | EP | disclosed |
| US-10335503-B2 | Compound that specifically binds to AMPA receptor | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20180200391-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2018-07-19 | — | — | US | disclosed |
| US-20180200391-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3321252-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | Public University Corporation Yokohama City University (JP) | 2018-05-16 | — | — | EP | disclosed |
| WO-2017006931-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | 公立大学法人横浜市立大学 | 2017-01-12 | — | — | WO | disclosed |
| EP-0811375-B1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA LTD (JP) | 2001-01-03 | — | — | EP | disclosed |
| US-5955505-A | TREATING NERVE DEGENERATIVE DISORDERS | NIPPON SUISAN KAISHA, LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| EP-0811375-A1 | GLUTAMIC ACID RECEPTOR AGONIST | NIPPON SUISAN KAISHA, LTD. (JP) | 1997-12-10 | — | — | EP | disclosed |
| EP-0469901-B1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5189211-A | Thromboxane A2 antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1993-02-23 | — | — | US | disclosed |
| EP-0469901-A1 | Sulfonamide derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200391-A1 | NOVEL COMPOUND THAT SPECIFICALLY BINDS TO AMPA RECEPTOR | GRM3, GRM1, GRIN3A | ALDH1A1 2376/4885HSD17B10 2229/4885TDP1 4136/4885 |
| US-10335503-B2 | Compound that specifically binds to AMPA receptor | GRM3, GRIN3A, GRM1 | ALDH1A1 2218/4885HSD17B10 2432/4885TDP1 4288/4885 |
| US-20200384134-A1 | IMAGING METHOD OF AMPA RECEPTORS IN BRAIN OF PRIMATE ORGANISM, PROGRAM, DIAGNOSTIC AGENT, COMPANION DIAGNOSTIC AGENT, DRUG, SCREENING METHOD, INPUT TERMINAL, SERVER AND SYSTEM | SLC1A2, SLC1A1, SLC1A3 | ALDH1A1 1454/4885HSD17B10 4041/4885TDP1 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.